Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

Zepbound is Eli Lilly’s weight loss drug. Now, it is also a drug to treat obstructive sleep apnea (OSA).The U.S. Food and ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...

Meanwhile, Vertex Pharmaceuticals received a nod from the FDA for its triple combination cystic fibrosis treatment, marking a ...

Lilly investors got the jitters, saw better opportunities elsewhere, or decided to hold onto their chips. In the third ...

"Zepbound is the first medication that significantly improves moderate-to-severe OSA and aids in long-term weight loss in ...

FOX 8 News’ Wayne Dawson is sharing an update on his health after receiving a surprising diagnosis of oral cancer earlier ...

The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

A key competitiveness of Zepbound lies in that it is the only US FDA-approved product that activates both GLP-1 and GIP - two receptors playing key roles in regulating blood sugar and energy ...